Cambrex investment continues as industry trends ‘remain favorable’

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Olivier Le Moal)
(Image: iStock/Olivier Le Moal)

Related tags Investment

The latest in a series of investments, Cambrex has recently expanded its Sweden-based site as part of its ongoing investment in small molecule API manufacturing across its global network of facilities. 

As In-PharmaTechnologist.com previously​ reported, the company will spend $9m to add large-scale manufacturing capability as its API production facility in Karlskoga, Sweden.

This investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities​,” a spokesperson from the company told this publication.

Specifically, there continues to be high demand for US- and European-based suppliers with large scale cGMP contract manufacturing capacity and “world class quality systems​.” 

Prior to investing in the new facility, the company considered several factors, such as the value of the products manufactured, the customer base and the customers’ current and anticipated requirements, location, in addition to operating costs.

According to the company spokesperson, Cambrex is confident that the expansion “will be well utilized​.”

In addition to its investment in Karlskoga, the company recently completed construction on a $50m production and warehousing expansion at its Charles City, Iowa-based cGMP site.

We believe that our recent investments, combined with a very talented and experienced team, provides an ongoing foundation for our customers’ small molecule product manufacturing needs while supporting our goal of bringing our customers’ products to market quickly​,” the Cambrex spokesperson said.

As overall industry trends remain favorable, we will continue to invest to increase our small and large scale capabilities​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars